MOTS-c for Fat Loss in 2026: Dosage, Timing & Research

Important Disclaimer: The information on this site is for educational and research purposes only. Peptides discussed here are not approved by the FDA for human use outside of clinical trials. They are sold strictly for laboratory and research purposes. This is not medical advice. Always consult a licensed healthcare professional before considering any peptide, supplement, or research compound. We do not endorse or recommend personal use.

Introduction: The Mitochondrial Revolution in Fat Loss Research

Imagine a compound that tricks your cells into thinking you just finished an intense workout, even while you sit reading this article. A peptide that speaks directly to your mitochondria, the ancient energy factories buried within every cell, commanding them to burn fat more efficiently and restore the metabolic flexibility of your younger years.

This is MOTS-c, and researchers are paying close attention.

First identified in 2015 by Dr. Pinchas Cohen's team at the University of Southern California, MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) represents something genuinely novel in metabolic research. Unlike most peptides encoded by nuclear DNA, MOTS-c originates from the mitochondrial genome itself, making it one of the first discovered mitochondrial derived peptides (MDPs) with direct metabolic signaling capabilities.

The research implications are significant. Studies in animal models demonstrate that MOTS-c administration prevents diet-induced obesity, dramatically improves insulin sensitivity, and activates the same AMPK pathways triggered by exercise and fasting. For biohackers and researchers exploring metabolic optimization, MOTS-c occupies a unique space: a naturally occurring peptide that declines with age, potentially offering restoration rather than enhancement.

This guide examines the current research landscape around MOTS-c for fat loss applications. We explore the 5 to 15mg dosage range commonly discussed in research protocols, optimal timing strategies for mitochondrial impact, combination approaches, and what the science actually supports versus what remains speculative. Whether you are a researcher designing protocols or an informed biohacker evaluating your options, this comprehensive breakdown delivers the evidence-based insights you need.

Key Insight: MOTS-c is the only known mitochondrial-derived peptide directly linked to exercise adaptation and metabolic homeostasis in multiple preclinical studies.

What Is MOTS-c? Understanding the Mitochondrial Messenger

MOTS-c is a 16-amino acid peptide encoded within the 12S rRNA region of mitochondrial DNA. This origin matters because it represents a form of retrograde signaling, where mitochondria communicate outward to influence nuclear gene expression and systemic metabolism rather than simply receiving instructions from the nucleus.

The peptide sequence (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) remains highly conserved across mammalian species, suggesting important biological functions that evolved to remain stable over millions of years. Interestingly, a genetic polymorphism in Japanese populations (m.1382A>C) affecting MOTS-c structure has been linked to increased longevity, providing epidemiological support for the peptide's role in healthy aging.

Under normal conditions, MOTS-c exists primarily in the cytoplasm. However, when cells experience metabolic stress, such as glucose restriction, oxidative challenges, or energy depletion, MOTS-c rapidly translocates to the nucleus within 30 minutes. There, it interacts with transcription factors containing antioxidant response elements (ARE), essentially helping cells adapt to metabolic challenges.

The peptide's primary target tissue is skeletal muscle, which aligns with its role as an exercise-induced signal. During physical activity, skeletal muscle MOTS-c levels surge approximately 12-fold, with circulating levels remaining elevated for several hours post-exercise. This dramatic increase positions MOTS-c as nature's own exercise mimetic molecule.

How MOTS-c Drives Fat Loss: Mechanisms of Action

The fat-burning potential of MOTS-c operates through several interconnected pathways, with AMPK activation serving as the central mechanism.

AMPK: The Metabolic Master Switch

AMPK (5' AMP-activated protein kinase) functions as the body's fuel gauge. When cellular energy runs low, AMPK activates to restore balance by stimulating energy-producing pathways while inhibiting energy-consuming processes. MOTS-c achieves AMPK activation through an elegant biochemical cascade.

The peptide targets the folate-methionine cycle, reducing levels of 5-methyltetrahydrofolate and disrupting de novo purine biosynthesis. This disruption elevates endogenous AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a natural AMPK activator that mimics the effects of metformin. The result is sustained AMPK activation independent of actual energy depletion.

When AMPK activates, downstream effects cascade throughout the body. GLUT4 glucose transporters mobilize to cell membranes, enhancing glucose uptake in muscle tissue. Beta-oxidation of fatty acids increases, shifting the body toward fat as a primary fuel source. Simultaneously, AMPK inhibits mTOR-dependent anabolic processes that consume energy, creating a metabolic state resembling what happens during fasting or vigorous exercise.

Key Insight: MOTS-c shares physiological similarities with metformin in regulating glucose utilization and body weight, but targets skeletal muscle directly rather than the liver.

Fat Oxidation and Insulin Sensitivity

Research published in Cell Metabolism demonstrated that MOTS-c treatment in mice fed high-fat diets prevented weight gain, reduced fat accumulation, and improved overall metabolic parameters (Lee et al., 2015). The specificity of fat loss was notable; MOTS-c appeared to preferentially target adipose tissue without compromising lean mass.

The insulin-sensitizing effects operate at multiple levels. In skeletal muscle, MOTS-c enhances glucose uptake and clearance while improving the cellular response to insulin signaling. Studies using hyperinsulinemic-euglycemic clamp techniques, the gold standard for measuring insulin action, confirmed that MOTS-c regulates glucose homeostasis by targeting skeletal muscle to increase clearance rather than reducing hepatic production.

A 2019 metabolomics study revealed that MOTS-c treatment significantly altered plasma metabolite profiles in diet-induced obese mice (Kim et al., 2019). Three pathways, including sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism, showed reduced activity following MOTS-c administration. These same pathways are typically upregulated in obesity and type 2 diabetes models, suggesting MOTS-c helps normalize metabolic dysfunction.

The Exercise Mimetic Effect

Perhaps the most compelling aspect of MOTS-c research is its classification as an exercise mimetic. This designation means the peptide triggers many of the same cellular adaptations that occur with physical training, even in the absence of actual exercise.

A landmark 2021 study published in Nature Communications demonstrated that MOTS-c treatment enhanced physical capacity and improved metabolic homeostasis in both young and aged mice (Reynolds et al., 2020). Remarkably, older mice treated with MOTS-c showed exercise performance comparable to younger animals, suggesting the peptide can counteract age-related declines in metabolic flexibility.

The mechanisms underlying this effect involve mitochondrial biogenesis, the creation of new mitochondria within cells. AMPK activation through MOTS-c stimulates PGC-1α, a master regulator of mitochondrial creation, leading to increased cellular energy production capacity. More mitochondria means more efficient fat burning and greater exercise tolerance.

Human studies examining endogenous MOTS-c levels support these findings. Research involving breast cancer survivors showed that exercise intervention significantly increased circulating MOTS-c levels, which correlated positively with improvements in lean mass, fat loss, and insulin sensitivity markers (D'Souza et al., 2021).

MOTS-c Dosage Protocols: The 5–15mg Research Range

Understanding optimal MOTS-c dosing requires acknowledging a critical limitation: no large-scale human clinical trials have established definitive protocols. Current dosing guidance derives from animal studies, early human trials with the MOTS-c analog CB4211, and accumulated anecdotal reports from the research community.

Translating Animal Research to Human Contexts

Preclinical studies typically used doses ranging from 2.5 mg/kg to 15 mg/kg body weight in mice, administered intraperitoneally multiple times weekly. Direct translation to humans requires accounting for metabolic differences, generally suggesting human-equivalent doses 10-fold or more lower than rodent doses on a per-kilogram basis.

The CB4211 Phase 1a/1b trial (NCT03998514) provides the most relevant human data available. This study tested a modified MOTS-c analog in obese subjects with fatty liver disease, using 25 mg daily subcutaneous injections for 28 days. The trial met its primary safety endpoint, with the drug proving well-tolerated aside from mild injection site reactions (CohBar, 2021).

Research Protocol Recommendations

Based on current evidence, research protocols commonly discuss the following MOTS-c dosing parameters:

The 5mg starting dose represents the minimum threshold where metabolic effects become observable based on extrapolation from preclinical data. Researchers often begin here to establish individual tolerance before increasing.

Weekly totals in the 5 to 15mg range align with the theoretical human equivalent of effective animal doses. Some protocols split this into 2 to 3 injections per week (for example, Monday, Wednesday, Friday), while others use every 5-day administration for more spaced dosing.

Key Insight: Research suggests doses exceeding 15mg weekly do not consistently produce superior outcomes and may increase side effect likelihood without proportional benefit.

Cycling Considerations

Most discussed protocols incorporate cycling phases to prevent potential receptor desensitization and maintain efficacy. A common approach involves 4 to 6 weeks on-cycle followed by 2 to 4 weeks off before repeating. This pattern theoretically allows receptors to recover sensitivity while providing accumulated metabolic benefits during active phases.

Some researchers advocate for longer cycles of 8 to 12 weeks given MOTS-c's mechanism of action through AMPK rather than direct receptor binding. The optimal cycling duration remains unclear without controlled human studies, making self-experimentation the current reality for most users.

Learn more about cycling strategies in our peptide glossary entry on cycling.

Timing Protocols: When to Administer MOTS-c for Maximum Impact

Strategic timing of MOTS-c administration can theoretically optimize its metabolic effects by aligning with the body's natural circadian rhythms and metabolic states.

Morning Fasted Administration

The most commonly recommended timing involves morning injection on an empty stomach. This approach offers several theoretical advantages. AMPK activity and insulin sensitivity naturally peak in morning hours, meaning MOTS-c administration during this window may synergize with existing metabolic patterns. Fasting states already prime AMPK pathways, potentially amplifying MOTS-c effects.

Morning timing also prevents any energizing effects from interfering with sleep, a practical consideration given reports of increased daytime energy following MOTS-c administration. Some users describe a subtle stimulant-like quality, making afternoon or evening dosing potentially problematic for sleep quality.

Pre-Exercise Timing

An alternative protocol involves administration 30 to 60 minutes before fasted cardiovascular training. This timing leverages the synergy between MOTS-c's exercise-mimetic properties and actual physical activity. Research showing 12-fold increases in endogenous MOTS-c during exercise suggests the body naturally elevates this peptide when metabolic demands increase.

Combining exogenous MOTS-c with exercise may create an amplified metabolic state where fat oxidation pathways receive signaling from both internal and external sources. This approach is particularly popular among biohackers seeking to maximize training adaptation and fat loss during cutting phases.

Practical Timing Recommendations

Consistency matters more than perfect timing. Choose a protocol that fits your lifestyle and maintain it throughout your research cycle. Whether morning fasted, pre-workout, or another approach, regular administration appears more important than hitting specific windows.

If stacking MOTS-c with other peptides, inject at different anatomical sites to prevent any potential interactions at the injection location. Some researchers separate MOTS-c from growth hormone secretagogues by several hours to avoid any theoretical interference with signaling pathways.

Combining MOTS-c: Stack Protocols and Synergistic Approaches

MOTS-c can be incorporated into broader peptide protocols targeting fat loss, metabolic health, and longevity. Understanding potential synergies helps researchers design comprehensive approaches.

MOTS-c + Tesamorelin: The Visceral Fat Protocol

Combining MOTS-c with Tesamorelin creates a dual-mechanism approach to fat reduction. Tesamorelin, an FDA-approved growth hormone-releasing hormone analog, specifically targets visceral adipose tissue. MOTS-c enhances overall metabolic flexibility and insulin sensitivity through AMPK activation.

This combination addresses fat loss from two distinct angles: Tesamorelin stimulates growth hormone release to mobilize stored fat, while MOTS-c improves the cellular machinery responsible for oxidizing that released fat. Research clinics sometimes recommend this stack for individuals with stubborn abdominal adiposity.

MOTS-c + CJC-1295/Ipamorelin: Growth Hormone Enhancement

Pairing MOTS-c with the CJC-1295 and Ipamorelin combination offers metabolic optimization alongside growth hormone support. The GH secretagogues promote pulsatile hormone release supporting fat metabolism and muscle preservation, while MOTS-c provides the mitochondrial enhancement that ensures efficient energy utilization.

This stack may be particularly relevant for aging individuals experiencing both declining MOTS-c levels and reduced growth hormone output. By addressing multiple age-related metabolic declines simultaneously, the combination theoretically offers more comprehensive restoration.

MOTS-c vs. GLP-1 Agonists: Different Mechanisms, Different Applications

MOTS-c and GLP-1 receptor agonists like Semaglutide or Tirzepatide represent fundamentally different approaches to fat loss. GLP-1 agonists work through appetite suppression, delayed gastric emptying, and incretin hormone modulation. MOTS-c operates at the cellular metabolism level, enhancing how cells utilize fuel rather than reducing intake.

Some researchers explore combining both approaches, using GLP-1 agonists for appetite control while adding MOTS-c for metabolic enhancement. This combination theoretically addresses both energy intake and expenditure, though no formal studies have examined the interaction.

Ready to Track Your Peptide Research? Explore vetted sources for MOTS-c and calculate your reconstitution needs with our Reconstitution Calculator. For research purposes only.

Clinical Evidence: What Human Studies Reveal

While MOTS-c itself has not completed Phase 2 or Phase 3 human trials, related research provides insights into its potential efficacy and safety profile.

The CB4211 Trial: Proof of Concept

CohBar's Phase 1a/1b trial of CB4211, a stabilized MOTS-c analog, offers the most direct evidence for MOTS-c-based therapeutics in humans. The study enrolled 20 obese participants with at least 10% liver fat, comparing 25 mg daily subcutaneous injections against placebo over 28 days (ClinicalTrials.gov NCT03998514).

Results demonstrated that CB4211 met its primary safety endpoints with no serious adverse events. Exploratory efficacy measures showed promising trends. Relative to placebo, liver enzyme levels (ALT and AST) declined by 25% and 17% respectively, suggesting reduced hepatic stress. Fasting glucose levels also improved, consistent with enhanced insulin sensitivity.

Liver fat reduction measured by MRI showed roughly 5% decreases in both treatment and placebo groups, failing to demonstrate clear superiority for CB4211 on this measure. However, approximately 36% of CB4211-treated patients achieved greater than 30% relative liver fat reduction, compared to lower rates in placebo. The short study duration may have limited ability to detect longer-term composition changes.

Observational Human Data

Several observational studies examining endogenous MOTS-c levels support its metabolic relevance. Plasma MOTS-c concentrations correlate inversely with body mass index, fasting insulin, and glycosylated hemoglobin in human cohorts. Lower MOTS-c levels associate with obesity and metabolic dysfunction across multiple populations.

Research in breast cancer survivors demonstrated that structured exercise programs increase circulating MOTS-c levels, with these increases correlating to improvements in body composition and insulin sensitivity markers. These findings suggest that boosting MOTS-c, whether through exercise or exogenous administration, may produce measurable metabolic benefits.

Key Insight: While direct evidence remains preliminary, multiple lines of research converge to support MOTS-c's role in metabolic regulation and its potential as a therapeutic target.

Side Effects and Safety Considerations

MOTS-c benefits from being a naturally occurring, endogenously produced peptide. This origin suggests inherent biological compatibility, though exogenous administration introduces considerations that natural production avoids.

Reported Side Effects

Based on the CB4211 trial and accumulated user reports, side effects appear relatively mild for most individuals:

Common effects include injection site reactions, with redness, swelling, or mild irritation reported frequently in the CB4211 trial. These reactions were described as persistent but painless, sometimes lasting several days before resolution. Rotating injection sites minimizes this issue.

Some users report initial fatigue or lethargy during the first few days of administration, potentially reflecting adjustment to altered metabolic signaling. This typically resolves within a week as the body adapts.

Hunger changes vary between individuals. Some experience appetite suppression consistent with enhanced metabolic efficiency, while others report increased hunger possibly reflecting enhanced fat mobilization and energy expenditure.

Theoretical Concerns

Because MOTS-c activates AMPK, similar pathways affected by metformin, potential interactions exist with diabetes medications or other compounds affecting blood glucose. Individuals using insulin sensitizers should monitor glucose levels carefully and work with healthcare providers when considering MOTS-c research.

Extended high-dose usage could theoretically lead to excessive AMPK activation, though no evidence currently suggests this occurs at typical research doses. Cycling protocols may help prevent any potential accumulation effects.

MOTS-c is prohibited by WADA under Section 4.4 (Metabolic Modulators) as an AMPK activator. Athletes subject to drug testing should avoid this peptide entirely.

Reconstitution and Administration

MOTS-c typically arrives as a lyophilized (freeze-dried) powder requiring reconstitution before use. Proper handling preserves peptide integrity and ensures accurate dosing.

Reconstitution Protocol

To reconstitute a 10mg MOTS-c vial:

Prepare bacteriostatic water. Adding 2mL yields a concentration of 5mg/mL. Adding 1mL yields 10mg/mL. Choose based on your intended dose volumes.

Wipe both vial stoppers with alcohol swabs. Using a sterile syringe, slowly inject bacteriostatic water along the vial wall, allowing it to trickle down rather than directly onto the powder. Avoid shaking or agitating, instead gently swirling until fully dissolved. The solution should appear clear.

Use our Reconstitution Calculator to determine exact water volumes for your desired concentration.

Storage Requirements

Lyophilized powder should be stored frozen at -20°C (-4°F) for long-term stability. Properly stored, unreconstituted MOTS-c remains stable for 2+ years.

Once reconstituted, refrigerate at 2 to 8°C (35 to 46°F) and use within 21 to 28 days. Never freeze reconstituted solution, as this destroys peptide structure. Protect from light exposure during storage.

Injection Technique

MOTS-c is administered via subcutaneous injection into fatty tissue. Common sites include the abdominal region (at least 2 inches from the navel), outer thigh, or back of the upper arm. Use insulin syringes (29 to 31 gauge) for comfortable injection.

Rotate injection sites systematically to prevent irritation and lipohypertrophy. Clean the injection site with alcohol, pinch a skin fold, insert the needle at 90 degrees (45 degrees if very lean), inject slowly, and apply gentle pressure after withdrawal if bleeding occurs.

For more guidance on syringe measurements, visit our Syringe Converter Tool.

MOTS-c for Longevity: Beyond Fat Loss

While fat loss represents the most actively researched application, MOTS-c's effects extend into broader longevity and anti-aging domains.

Age-Related Decline

Endogenous MOTS-c levels decline naturally with aging, paralleling reductions in mitochondrial function, insulin sensitivity, and metabolic flexibility. This decline may contribute to the metabolic dysfunction that characterizes aging, including increased susceptibility to obesity, type 2 diabetes, and cardiovascular disease.

Studies in aged mice demonstrate that MOTS-c administration can reverse age-dependent insulin resistance, restoring metabolic parameters to levels comparable with younger animals. These findings suggest MOTS-c may address fundamental aspects of metabolic aging rather than merely masking symptoms.

The peptide's effects on myostatin, a negative regulator of muscle mass, provide additional longevity relevance. Research shows MOTS-c treatment decreases myostatin levels, potentially protecting against age-related muscle wasting (sarcopenia) while simultaneously improving metabolic health (Kim et al., 2021).

Cardiovascular Implications

Emerging research connects MOTS-c to cardiovascular protection. The peptide improves endothelial function and may protect cardiac tissue under metabolic stress conditions. Studies suggest MOTS-c treatment prevents heart failure development in mouse models, effects attributed to AMPK activation in cardiac tissue and improved mitochondrial function.

These cardiovascular benefits align with the broader understanding that metabolic health and cardiovascular health are deeply intertwined. Improving insulin sensitivity, reducing inflammation, and enhancing mitochondrial function through MOTS-c may produce protective effects extending well beyond fat loss.

Practical Application: Research Protocol Summary

For researchers designing MOTS-c protocols, here is a consolidated practical framework:

Beginner Protocol

Start with 5mg every 5 days, administered subcutaneously in the morning on an empty stomach. Continue for 20 days (4 doses total), then assess tolerance and effects before considering escalation. This conservative approach establishes individual response patterns with minimal risk.

Standard Fat Loss Protocol

Administer 5 to 10mg twice weekly (for example, Monday and Thursday or Tuesday and Friday), injected subcutaneously 30 to 60 minutes before fasted morning cardio or upon waking. Continue for 4 to 8 weeks before cycling off for 2 to 4 weeks. Total weekly dose falls within the 10 to 20mg range.

Advanced Stack Protocol

Combine MOTS-c 10mg twice weekly with CJC-1295/Ipamorelin (100mcg each daily in the evening) and Tesamorelin (2mg daily in the evening). This comprehensive approach targets fat loss through multiple complementary pathways. Run for 8 to 12 weeks with appropriate cycling of each component.

Optimize Your Research Protocols Calculate cycle duration and track your research with our Cycle Duration Estimator. For research purposes only.

Frequently Asked Questions

How quickly does MOTS-c work for fat loss?

Based on mechanism and user reports, initial effects on energy and metabolic markers may emerge within 2 to 4 weeks. Meaningful body composition changes typically require 6 to 12 weeks of consistent use combined with appropriate diet and exercise.

Can MOTS-c replace exercise?

While MOTS-c activates exercise-like pathways, it does not replicate all exercise benefits including cardiovascular conditioning, neuromuscular adaptation, and psychological effects. Consider it a supplement to rather than replacement for physical activity.

Is MOTS-c legal?

MOTS-c is not FDA-approved for human use and is sold for research purposes only. It is prohibited for use by athletes under WADA guidelines. Legal status varies by jurisdiction; always verify local regulations.

How does MOTS-c compare to AOD-9604?

AOD-9604 is a growth hormone fragment targeting fat metabolism without affecting IGF-1 levels. MOTS-c works through AMPK activation and mitochondrial enhancement. They address fat loss through different mechanisms and can be combined in research protocols.

What is the half-life of MOTS-c?

Endogenous MOTS-c appears to have a circulating half-life of approximately 1 to 2 hours based on post-exercise clearance patterns. Reconstituted solutions remain stable for approximately 3 to 4 weeks when refrigerated.

Optimize Your Research Protocols Calculate cycle duration and track your research with our Cycle Duration Estimator. For research purposes only.

Frequently Asked Questions

How quickly does MOTS-c work for fat loss?

Based on mechanism and user reports, initial effects on energy and metabolic markers may emerge within 2 to 4 weeks. Meaningful body composition changes typically require 6 to 12 weeks of consistent use combined with appropriate diet and exercise.

Can MOTS-c replace exercise?

While MOTS-c activates exercise-like pathways, it does not replicate all exercise benefits including cardiovascular conditioning, neuromuscular adaptation, and psychological effects. Consider it a supplement to rather than replacement for physical activity.

Is MOTS-c legal?

MOTS-c is not FDA-approved for human use and is sold for research purposes only. It is prohibited for use by athletes under WADA guidelines. Legal status varies by jurisdiction; always verify local regulations.

How does MOTS-c compare to AOD-9604?

AOD-9604 is a growth hormone fragment targeting fat metabolism without affecting IGF-1 levels. MOTS-c works through AMPK activation and mitochondrial enhancement. They address fat loss through different mechanisms and can be combined in research protocols.

What is the half-life of MOTS-c?

Endogenous MOTS-c appears to have a circulating half-life of approximately 1 to 2 hours based on post-exercise clearance patterns. Reconstituted solutions remain stable for approximately 3 to 4 weeks when refrigerated.

Conclusion: The Future of Mitochondrial Medicine

MOTS-c represents a genuinely novel approach to metabolic optimization, one that works from the inside out by targeting the cellular machinery responsible for energy production and fuel selection. The research supporting its role in fat metabolism, insulin sensitivity, and exercise adaptation continues to accumulate, even as human clinical data remains preliminary.

For biohackers and researchers, MOTS-c offers something rare: a naturally occurring peptide that declines with age, meaning supplementation represents restoration of normal biology rather than pushing beyond natural limits. The 5 to 15mg weekly dosing range, combined with strategic timing around fasting and exercise, provides a framework for exploring this compound's potential.

The cautions are equally important. Human trial data remains limited, long-term effects are unknown, and individual responses vary significantly. Anyone considering MOTS-c research should approach it with appropriate skepticism, proper medical oversight, and realistic expectations about what current evidence supports.

As mitochondrial medicine advances, MOTS-c stands at the forefront of a new understanding: that our cellular energy systems can be optimized, that the age-related decline in metabolic function is not inevitable, and that the same pathways activated by exercise and fasting can be engaged pharmacologically. The research continues, and the implications for fat loss, longevity, and human performance remain compelling.

Final Note: Research peptides carry risks and are not intended for human consumption outside regulated studies. Individual results vary. This article is based on publicly available scientific literature and user-reported experiences—it is not a substitute for professional medical guidance.

References

1. Lee, C., Zeng, J., Drew, B.G., et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3), 443-454. https://doi.org/10.1016/j.cmet.2015.02.009
2. Reynolds, J.C., Lai, R.W., Woodhead, J.S.T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. https://doi.org/10.1038/s41467-020-20790-0
3. Kim, S.J., Miller, B., Mehta, H.H., et al. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13), e14171. https://doi.org/10.14814/phy2.14171
4. Kim, S.J., Xiao, J., Wan, J., et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology-Endocrinology and Metabolism, 320(4), E680-E690. https://doi.org/10.1152/ajpendo.00275.2020
5. Wan, W., Zhang, L., Lin, Y., et al. (2023). Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 21, 36. https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/
6. Kong, B.S., Lee, C., & Cho, Y.M. (2023). Mitochondrial-encoded peptide MOTS-c, diabetes, and aging-related diseases. Diabetes & Metabolism Journal, 47(3), 315-324. https://doi.org/10.4093/dmj.2022.0333
7. D'Souza, R.F., Woodhead, J.S.T., Hedges, C.P., et al. (2021). Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports, 11, 16924. https://doi.org/10.1038/s41598-021-96419-z
8. Lu, H., Wei, M., Zhai, Y., et al. (2019). MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine, 97(4), 473-485. https://doi.org/10.1007/s00109-018-01738-w
9. ClinicalTrials.gov. NCT03998514: A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. https://clinicaltrials.gov/study/NCT03998514
10. Mohtashami, Z., Singh, M.K., Salimiaghdam, N., et al. (2022). MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. International Journal of Molecular Sciences, 23(19), 11991. https://doi.org/10.3390/ijms231911991
11. USADA. (2024). What is the MOTS-c peptide? United States Anti-Doping Agency. https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/
12. Kim, M.S. (2022). Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). Diabetes & Metabolism Journal, 46(3), 402-413. https://pmc.ncbi.nlm.nih.gov/articles/PMC9171157/